Myocarditis secondary to the use of immunotherapy: ipilimumab and nivolumab

Alfredo Kim Gálvez Medina; Susana Padilla Ávila; Juan Pablo Feregrino Arreola; Núñez Urquiza,Juan Pablo; Rafael Vera Urquiza

2026, Number 3

<< Back Next >>

Acta Med 2026; 24 (3)

Myocarditis secondary to the use of immunotherapy: ipilimumab and nivolumab

Gálvez MAK, Padilla ÁS, Feregrino AJP, Núñez UJP, Vera UR

Full text

How to cite this article

10.35366/123156

Language: Spanish
References: 0
Page: 293-295
PDF size: 1180.01 Kb.

ABSTRACT

Immune checkpoint inhibitors (ICI)-related myocarditis is quite an infrequent, but fatal, adverse effect with a reported incidence of 0.04-1.14%. Therefore, there are only a few cases in literature described thoroughly. Here we present a case report of a 51-year-old male with epidermoid lung carcinoma who, after being treated with nivolumab and ipilimumab, suffers a case of myocardiopathy secondary to ICI. In conclusion, we consider necessary the development of detailed guidelines for the treatment of this pathology whose incidence, as well as the use of ICI, shall increase.